Patient-reported outcome-informed individualized dose and schedule modification of enfortumab vedotin plus pembrolizumab in a nonagenarian patient with metastatic bladder cancer: a case report.

Abstract

Treatment opportunities using the enfortumab vedotin plus pembrolizumab (EV+P) combination are expanding for patients with unresectable or metastatic urothelial carcinoma. We report the case of a 93-year-old man with bladder cancer and lung metastases who received EV+P therapy and achieved a complete response. By omitting the dose on EV Day 8 and then extending the dosing interval based on adverse events and patient-reported outcomes, it was possible to continue treatment while maintaining complete response.